GAL and metabolic dysfunction-associated steatotic liver disease: reported GAL-3BP increase in NAFLD patients between three groups (PostM-NAFLD vs. PostM-Control, PreM-NAFLD vs. PreM-Control, and PostM-NAFLD vs. PreM-NAFLD).